1. Home
  2. DGLY vs ENTO Comparison

DGLY vs ENTO Comparison

Compare DGLY & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DGLY
  • ENTO
  • Stock Information
  • Founded
  • DGLY 2004
  • ENTO 2014
  • Country
  • DGLY United States
  • ENTO United Kingdom
  • Employees
  • DGLY N/A
  • ENTO N/A
  • Industry
  • DGLY Radio And Television Broadcasting And Communications Equipment
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DGLY Technology
  • ENTO Health Care
  • Exchange
  • DGLY Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • DGLY 2.8M
  • ENTO 2.3M
  • IPO Year
  • DGLY N/A
  • ENTO 2016
  • Fundamental
  • Price
  • DGLY $1.25
  • ENTO $2.61
  • Analyst Decision
  • DGLY
  • ENTO
  • Analyst Count
  • DGLY 0
  • ENTO 0
  • Target Price
  • DGLY N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • DGLY 39.9K
  • ENTO 93.1K
  • Earning Date
  • DGLY 12-29-2025
  • ENTO 11-19-2025
  • Dividend Yield
  • DGLY N/A
  • ENTO N/A
  • EPS Growth
  • DGLY N/A
  • ENTO N/A
  • EPS
  • DGLY N/A
  • ENTO N/A
  • Revenue
  • DGLY $19,097,965.00
  • ENTO N/A
  • Revenue This Year
  • DGLY N/A
  • ENTO N/A
  • Revenue Next Year
  • DGLY $7.38
  • ENTO N/A
  • P/E Ratio
  • DGLY N/A
  • ENTO N/A
  • Revenue Growth
  • DGLY N/A
  • ENTO N/A
  • 52 Week Low
  • DGLY $1.08
  • ENTO $2.40
  • 52 Week High
  • DGLY $1,960.00
  • ENTO $4.56
  • Technical
  • Relative Strength Index (RSI)
  • DGLY 24.18
  • ENTO 33.45
  • Support Level
  • DGLY $1.20
  • ENTO $3.56
  • Resistance Level
  • DGLY $1.34
  • ENTO $3.89
  • Average True Range (ATR)
  • DGLY 0.10
  • ENTO 0.46
  • MACD
  • DGLY -0.03
  • ENTO -0.16
  • Stochastic Oscillator
  • DGLY 22.76
  • ENTO 11.11

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: